Evidence, safety, legality

Is Ibogaine a Psychedelic?

A calm, evidence-first look at a psychoactive compound from the iboga plant: its oneirogenic effects, addiction treatment interest, and serious cardiac risks.

36hProlonged dream-like state commonly reported during acute dosing
Poly-Pharmacology across serotonin receptors, dopamine, and glutamate
QT↑Cardiac risk via QT interval prolongation demands medical supervision
Ibogaine topic visual set against a dark architectural composition
Classification, mechanism, experience, and cardiac caution

How to reach Psychedelic Ibogaine

We welcome corrections, clarifications, and feedback on the site's informational content.

At this time there is no direct email or contact form published. The site can be reached through its published channels; please check back for contact details and updates. For information about our editorial approach and sourcing, see the page that outlines the project’s mission and methodology on our about page, which explains how Psychedelic Ibogaine compiles evidence and handles corrections.

For readers comparing treatment options and clinics, we note that directories and treatment listings can help identify licensed providers; for example, curated directories and treatment-center listings often highlight distinctions between medically supervised programs and informal clinics — always verify credentials and monitoring before engaging a program. This page links back to the site front door and editorial guidance; if you want broader navigation, return to the site index at the root to review other pages and resources on ibogaine and psychedelics: visit the site index.

Psychedelic Ibogaine is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice.